AbbVie Inc. Long-Term Investments Change (Net)

Long-Term Investments Change (Net) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-Term Investments Change (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Long-Term Investments Change (Net) for the quarter ending March 30, 2021 was $-5 Million (a -110.64% decrease compared to previous quarter)
  • Year-over-year quarterly Long-Term Investments Change (Net) decreased by -100.36%
  • Annual Long-Term Investments Change (Net) for 2020 was $1.46 Billion (a -30.81% decrease from previous year)
  • Annual Long-Term Investments Change (Net) for 2019 was $2.12 Billion (a 475.0% increase from previous year)
  • Annual Long-Term Investments Change (Net) for 2018 was $368 Million (a -34.64% decrease from previous year)
  • Twelve month Long-Term Investments Change (Net) ending March 30, 2021 was $1.45 Billion (a -1.23% decrease compared to previous quarter)
  • Twelve month trailing Long-Term Investments Change (Net) decreased by -51.88% year-over-year
Trailing Long-Term Investments Change (Net) for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$1.45 Billion $1.46 Billion $1.46 Billion $3.01 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-Term Investments Change (Net) of AbbVie Inc.

Most recent Long-Term Investments Change (Net)of ABBV including historical data for past 10 years.

Interactive Chart of Long-Term Investments Change (Net) of AbbVie Inc.

AbbVie Inc. Long-Term Investments Change (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-5.0
2020 $47.0 $20.0 $1,384.0 $13.0 $1,464.0
2019 $40.0 $1,568.0 $108.0 $400.0 $2,116.0
2018 $35.0 $-541.0 $830.0 $44.0 $368.0
2017 $511.0 $97.0 $481.0 $-526.0 $563.0
2016 $-15.0 $-24.0 $-1,608.0 $-1,309.0 $-2,956.0
2015 $18.0 $872.0 $-850.0 $8.0 $48.0
2014 $17.0 $1,151.0 $-200.0 $-660.0 $308.0
2013 $321.0 $-607.0 $486.0 $1,575.0 $1,775.0
2012 $-202.0 $-1,825.0 $1.0 $629.0 $-1,397.0
2011 $614.44 $622.27 $-1,936.86 $12.15 $-688.0
2010 $-92.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.